



# How improved information included pro-actively can help registrants more convincingly demonstrate the control of risk to authorities?

ENES 10, 15 November 2016




Se Al Cu Ni Pb Sn Zn Au Ag Pt Sb W Be Si Cr Co Mo Ge V Mn Ir Ru Rh Ta

## ENES and the CSR/ES roadmap, places to...

- Work further on the improvement of the quality of the information included in the registration dossiers and communicated along the supply chain
- Make best use of 'experience' and « best practices »
- Ensure coherence between the activities targeting the 2020 goals/Safe Use of Chemicals

# Some observations...

Starting point for REACH processes is the Registration dossier



Importance of 'concern' (incl. Exposure)

Good, up-to-date and complete information is essential but time, resources can be issues



# Development of a self-reflection/risk management « preparatory tool » for industry

- To apply **ahead** of any regulatory initiative:
  - more time to explore
  - more time to develop strategies
  - more leeway for creativity and discussions
- Focused on « **concerns** » but with ‘**risk management**’ as target
- Allowing **to optimise Registration dossier (preparation or update)**
  - Identify what counts to demonstrate/document risk management
  - Test the quality of the available data vs. a possible “RMOA”
  - Consider uncertainties on calculated values (DNEL, RCRs etc.)
- Allowing **to optimize input in regulatory processes**
  - Improves coordination of data collection and timely input
  - Allows to prepare for next steps (in case of Authorisation e.g.)

## Development of a self-reflection tool for industry (2)

- A 5 steps-strategy was developed, based on case studies

**Step 1 : Identify areas of concern**


**Step 2 : Identify potential Risk Management Options by use**

**Step 3 : Fitness tests of Risk Management Options**


**(Step 4 : Integration of RMMs/RMOas for different uses)**

**Step 5 : Conclusions and identification of available and missing data**

**Step 1 : look at your substance and identify areas of concern**



## Step 2: Selecting potential Risk Management Options by use



### Step 3: Fitness of Risk Management Options using criteria

- **Effectiveness:** Is the proposed option able to reduce possible risks and will the effects be measurable?
  - *Availability of proven and affordable technology, success cases for other substances*
- **Practicality:** Can the RMO be implemented easily?
  - *Clarity on actions to be undertaken to implement the RMO, enforceability and implementability for the regulators etc.*
- **Regulatory consistency:** Is the RMO consistent with a fairly level playing field across the EU and other EU legislation /policy?
  - *Risk of significant different national implementation? Any regulatory overlaps or gaps?*
- **Broader impacts:** Are there broader economic, human health and environmental impacts worth considering affecting the value chain or society?
  - *Indirect or collateral, beneficial or detrimental effects?*


### Step 4: Integrated approach for e.g. same use for different substances



## Step 5: Presenting the conclusions and identification of available and missing data


Potential RMO	CMR Workplace	OEL (binding)	Authorisation
Identified concern for substance X	Occupational exposure (example: acid mist exposure during plating)		
<b>Fitness</b>			
Effectiveness	++	++	++
Practicality	+	+	-
Regulatory consistency	-	++	++
Broader Impacts	+	+	-
<b>Approach</b>			
Non-Integrated	-	+	-
Integrated	++	+	+
Mixed	++	++	-
<b>Overall ranking and conclusions</b>	Preferred option: because most efficient and effective. Integrated/mixed approaches are OK	Second preferred option. Conclusion that here too a mixed approach is possible	Only an integrated approach might make sense

## STEP 5: Mapping existing data versus further information data needs to document risk management choices to cover 'concerns' and/or anticipate RMOa requests



# Use of the tool for respiratory sensitiser X

- **Aims: optimise 2018 Registration dossier & anticipate RMOAs**
  - Identify what counts to demonstrate/document risk management
  - Test the quality of the available data vs. a possible “RMOA”
  - Consider uncertainties on calculated values (DNEL, RCRs etc.)



# Step 5: Identification of data gaps

		REACH Registration	Accuracy	Uncertainty	Restriction	EQS	BATNEEC
Substance-related data	■	<ul style="list-style-type: none"> <li>Human Tox</li> <li>Regulations</li> </ul>	DNELS?	DNELS?	+	WFD data? +	BREFS?
		<ul style="list-style-type: none"> <li>Envi Tox</li> <li>Regulations</li> </ul>	DNELS?	DNELS?	+	++	
Process and functionality related data	■	<ul style="list-style-type: none"> <li>Volumes (overall)</li> <li><b>Exposure (generic)</b></li> <li>Process and product regulations</li> <li><b>Volumes per use / process</b></li> <li>Functionality per use/process</li> <li><b>Alternatives per use/process</b></li> </ul>	Reality?	Reality?	+	+	+
					+	+	+
Value chain-related data	■	<ul style="list-style-type: none"> <li># legal entities / plants</li> <li># <b>Workers exposed and dependent on substance use</b></li> <li><b>Market (volumes, trade)</b></li> <li>Price elasticity</li> <li>Cross-value chain interrelations</li> <li>Life-cycle dimensions (sustainability issues, recycling dynamics)</li> <li>Costs current vs. alternatives/non-use situation</li> <li>Costs current vs. new technology</li> </ul>			+	Regiona	+
					+	l	Tbc
					+	Populati	-
					+	on	-
					+	Tbc	-
					+	Tbc	+
					+	+	-
					If	-	+
					integrated	+	
					approach		

Not in Registration dossier

## Follow-up: actions taken or planned

### Exposure

- Epidemiological study
- Dermal monitoring campaign

### Volume/use; market info

- Survey at producers level
- Survey at DUs level

### Assessment of Alternatives

- AoA based on publicly available information, encourage companies to continue R&D

### Benefits at an early stage:

- Improvement of the registration dossier
- Better contribution in consultations and authorities RMO work

## To conclude



The tool is aimed to be used :

- As a ***critical mirror, self reflection*** for a sector/companies to define the potential need for risk management measures
- As an ***internal audit*** to allow a company to assess remaining risks & most efficient risk management measures
- Allowing to ***look from “all perspectives”*** for the need for risk management measures and relevant risk management options
- Allowing industry to ***anticipate*** “Member States -RMOas”
- As a tool to ***define the information required*** for an appropriate RMOa and probably lacking in the CSR
- As a tool to ***identify data gaps*** in or outside the registration dossiers
- As a tool for more ***risk management focused registrations*** (mainly for 2018 registrations)



Any question? Please contact :

Violaine: [verougstraete@eurometaux.be](mailto:verougstraete@eurometaux.be)

Hugo: [waeterschoot@eurometaux.be](mailto:waeterschoot@eurometaux.be)

THANK YOU



15

**Eurometaux**  
European Association of Metals

[www.eurometaux.eu](http://www.eurometaux.eu) | [www.callforaction.eu](http://www.callforaction.eu)

Avenue de Broqueville 12 | B-1150 Brussels | Tel: +32 (2) 775 63 11 | [eurometaux@eurometaux.be](mailto:eurometaux@eurometaux.be)